BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Embraer Boosts Aircraft Deliveries in Q4 2025, Signaling Strong Growth Into 2026 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
SOUTH SAN FRANCISCO, Calif., April 05, 2016 -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, announced today that it has appointed Rekha Hemrajani as Chief Operating Officer. She joins an experienced management team including Paul Kassner, Ph.D., Vice President, Quantitative Biology; David Wustrow, Ph.D., Vice President, Drug Discovery; Jordan Fridman, Ph.D., Chief Scientific Officer; William Ho, M.D., Ph.D., Chief Medical Officer; and Brian Wong, M.D., Ph.D., President and Chief Executive Officer.
"We are delighted to welcome Rekha to the management team at FLX Bio as the company advances its growing immuno-oncology and targeted oncology pipeline,” said Dr. Wong. “She brings extensive experience in biopharmaceutical corporate business development and financial operations that will be a great asset to our organization."
Hemrajani joins FLX Bio from 3-V Biosciences, where she served as Chief Financial Officer and Senior Vice President of Business and Financial Operations. Prior to her role at 3-V Biosciences, she served as Vice President, Head of Licensing and Mergers and Acquisitions at Onyx Pharmaceuticals, where she was responsible for corporate development strategy, search and evaluation, financial forecasting and analysis, competitive intelligence and transaction execution. Prior to Onyx, Hemrajani served as Vice President of Business Development at Exelixis, where she was involved in raising more than $800 million in capital through business development and other non-dilutive transactions. She has also served as a consultant to biotech companies and investors and has spent six years in investment banking at Credit Suisse First Boston and Lehman Brothers, helping companies of all sizes in the biopharmaceutical and healthcare industries raise capital in the public and private markets.
Hemrajani received her B.S. degree in Economics and Computer Science from the University of Michigan and her Master of Management degree from the Kellogg Graduate School of Management at Northwestern University.
About FLX Bio
Founded in 2015 following the acquisition of its predecessor company, Flexus Biosciences, Inc., by Bristol-Myers Squibb, FLX Bio, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents. The company leverages its unique insights into tumor pathways to develop novel oral medicines that activate the immune response to eliminate cancer cells.
Located in South San Francisco, Calif. and funded by leading investors, including Kleiner Perkins Caufield & Byers (KPCB), The Column Group (TCG), and Celgene, FLX Bio has assembled a management and leadership team with a proven track record of success and with substantial knowledge and expertise in the tumor microenvironment, drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.
Contact: Stephanie Ashe 650-245-0425 [email protected]
